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Introduction.The systemic inflammatory response (SIR) plays a key role in determining nutritional status and survival of patients
with cancer. A number of objective scoring systems have been shown to have prognostic value; however, their application in routine
clinical practice is not clear. The aim of the present survey was to examine the range of opinions internationally on the routine use
of these scoring systems. Methods. An online survey was distributed to a target group consisting of individuals worldwide who
have reported an interest in systemic inflammation in patients with cancer. Results. Of those invited by the survey (𝑛 = 238), 65%
routinely measured the SIR, mainly for research and prognostication purposes and clinically for allocation of adjuvant therapy or
palliative chemotherapy. 40% reported that they currently used the Glasgow Prognostic Score/modified Glasgow Prognostic Score
(GPS/mGPS) and 81% reported that ameasure of systemic inflammation should be incorporated into clinical guidelines, such as the
definition of cachexia. Conclusions.The majority of respondents routinely measured the SIR in patients with cancer, mainly using
the GPS/mGPS for research and prognostication purposes.Themajority reported that a measure of the SIR should be adopted into
clinical guidelines.
1. Introduction
Cancer remains amajor problemworldwide with 12.7million
new cases diagnosed in 2008. In the UK alone, 331,000
people were diagnosed with cancer in 2011 [1]. Despite major
advances in detection and treatment of cancer as well as
the introduction of several cancer screening programmes,
outcomes following cancer remain poor with only half of
people diagnosed with cancer surviving at 5 years [1].
Allocation of patients to the correct form of treatment,
be that surgical, oncological, or palliative, remains a difficult
decision. However, if patients were allocated to the most
appropriate treatment, then outcomes for all patients would
improve, irrespective of new, more effective treatments.
Traditionally, in those with early stage operable disease the
treatment decision has been made largely based on staging of
the cancer itself for example the Tumour, Node, Metastasis
(TNM) staging system whereas in advanced stage inoperable
disease the treatment decision has been made largely based
on the general health and fitness and whether the patient had
lost weight (cachexia).
In the last decade or so it has become apparent that a host
inflammatory response, in particular the systemic inflam-
matory response, plays a key role in determining cachexia
and the survival of patients with cancer [2, 3]. With this
new knowledge, a number of prognostic scoring systems that
provide an objective measurement of the systemic inflamma-
tory response have been developed and have been shown to
have prognostic value in patients with cancer. These include
the Glasgow Prognostic Score/modified Glasgow Prognos-
tic Score (GPS/mGPS), neutrophil-lymphocyte ratio (NLR),
platelet-lymphocyte ratio (PLR), white cell-lymphocyte ratio
(WLR), and others [4, 5]. The mGPS (combination of the
values of preoperative serumalbumin andC-reactive protein)
and the NLR (ratio of neutrophil and lymphocyte counts) are
the most widely reported prognostic scores worldwide and
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both have been shown to have prognostic value in a variety
of common solid tumours [6–8]. For example, by the end of
2012, the GPS/mGPS had been shown to have independent
prognostic value in cancer patients in 51 studies involving
28,500 patients [6]. Furthermore, the NLR has been shown
to have independent prognostic value in 100 studies involving
greater than 40 000 patients, with greater than 50% of these
studies published since the start of 2012 [9].
Despite the plethora of reported studies for these prog-
nostic scores, their value in routine clinical practice either
as tools to stratify patients in terms of outcomes or for
consideration for therapies such as adjuvant chemotherapy
or in clinical trials is not clear. With this in mind, the aim
of the present survey, in an international cohort, was to
examine the range of opinions on the routine use of systemic
inflammation based prognostic scoring systems and their
potential incorporation into clinical guidelines.
2. Methods
Aworldwide survey designed to establish opinions on the use
of systemic inflammation based prognostic scoring systems
was created. This was a web-based survey that included 10
questions on “systemic inflammation based prognostic scores
in cancer” as follows.
Survey Questions
(1) What is your discipline (surgeon/oncologist/patho-
logist, etc.) and in which country are you based?
(2) Do you or your colleagues routinely assess the sys-
temic inflammatory response as part of the clinical
assessment of patients with cancer?
Since 2008, could you estimate how many
patients have been assessed (a) in total and (b)
per year?
(3) If you answered yes to question (2), for what purpose?
Audit
Prognostication
Treatment Allocation
Research
(4) If you answered yes to question (2), what measure of
the systemic inflammatory response do you use?
GPS
NLR
Other
(5) Would you use a measure of the systemic inflamma-
tory response to stratify patients entering into clinical
trials?
(6) If you answered yes to question (5), which would you
prefer to use?
GPS
NLR
Other
(7) In which clinical scenario do you think a measure
of the systemic inflammatory response offers most
benefit to patients?
In making decisions about allocation of surgical
treatment for primary operable disease
In making decisions on allocation of neoadju-
vant treatment
In making decisions on allocation of adjuvant
treatment
Inmaking decisions on palliative chemotherapy
(8) Do you think that a measure of the systemic inflam-
matory response should be adopted into clinical
guidelines?
(9) If yes, which would you prefer to use?
GPS
NLR
Other
(10) If you do not think that a measure of the systemic
inflammatory response is useful in the routine clinical
assessment of cancer patients, please comment.
The survey was generated through the SurveyMonkey web-
site (http://www.surveymonkey.com/, SurveyMonkey, Paulo
Alto, USA) and the access link emailed to the target group.
The target group was selected primarily from two recent
reviews [6, 7] and by performing a more recent literature
search for articles using the keywords cancer, inflammation,
recurrence, survival, mGPS, and NLR. This literature search
was performed at the end of January 2014. Once a compre-
hensive list of articles was obtained, the email addresses of
corresponding authors from each article formed the basis of
amailing list for distribution.The email sent out clearly stated
that the aim of the survey was to establish whether there
was a role for the application of systemic inflammation based
prognostic scores in routine clinical practice and research
and that participation was voluntary. Software on the website
ensured duplication of responses from the same individual
was not recorded. No incentives were used to promote or
encourage participation.
The survey was first sent out on 26th February 2014 with a
reminder sent out one week later. The survey remained open
for 4 weeks and was closed on the 26thMarch 2014. Data was
analysed and graphs of results were compiled usingMicrosoft
Excel 2007 (Redmond, WA, USA).
3. Results
In February 2014, the survey was emailed to 238 individuals
worldwide who had published articles related to systemic
inflammation in patients with cancer. 43% were from Asia,
42% fromEurope, 12% fromAmerica, and 3% fromAustralia.
The response to survey question (1) is shown in Figures 1(a)
and 1(b). In total, 60 people completed the survey (25%). 26
respondents (43%) were surgeons, 15 (25%) oncologists, and
19 (32%) from other medical specialties. The proportion of
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Figure 1: (a) What is your discipline? (Respondents = 60) and (b) in which country are you based? (Respondents = 31).
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Figure 2: For what purpose do you measure the systemic inflammatory response? Respondents (𝑛 = 41).
respondents is shown in Figure 1(b) with 55% of respondents
being from Europe, 29% from Asia, 13% from Americas, and
3% from Australia.
In response to question (2), 39 (65%) of the respondents
answered yes that they routinely measured the systemic
inflammatory response in patients with cancer. The median
number of patients each participant assessed per year was 100
and the median number of patients each participant assessed
in total was 330.
The response to question (3) is shown in Figure 2. Of
the respondents, 11 (27%) reported its use for the purpose
of prognostication and research, 11 (27%) reported its use
for research purposes alone, 5 (12%) reported its use for the
purpose of prognostication alone, 4 (10%) reported its use for
audit purposes, and 3 (8%) reported its use for the purpose of
treatment allocation.
The response to question (4) is shown in Figure 3. Of
those who responded, 16 (40%) answered that the measure of
the systemic inflammatory response they used was the GPS,
8 (20%) the GPS/NLR, and 6 (15%) the NLR alone.
The response to question (5) is shown in Figure 4(a). Of
the respondents, 31 (56%) answered yes they would use a
measure of the systemic inflammatory response to stratify
patients entering clinical trials.
The response to question (6) is shown in Figure 4(b).
Of the respondents, 20 (57%) answered that they would use
the GPS, 4 (11%) the NLR, and 4 (11%) the GPS/NLR for
stratifying patients entering clinical trials.
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Figure 3: What measure of the systemic inflammatory response do
you use? Respondents (𝑛 = 40).
The response to question (7) is shown in Figure 5. Of
the respondents, 12 (25%) reported that the clinical scenarios
where a measure of the systemic inflammatory response
offers most benefit were making decisions on palliative
chemotherapy, 10 (21%) making decisions on allocation of
adjuvant therapy, 6 (12%) making decisions about either
adjuvant therapy or palliative chemotherapy, and 5 (10%) all
4 categories. Only 2 (4%) reported on making decisions on
allocation of surgical treatment.
The response to question (8) is shown in Figure 6(a). Of
the respondents, 46 (81%) answered yes to whether ameasure
of the systemic inflammatory response should be adopted
into clinical guidelines.
The response to question (9) is shown in Figure 6(b). Of
those who responded, 30 (60%) answered that themeasure of
the systemic inflammatory response they would prefer to use
in clinical guidelines was the GPS, 7 (14%) GPS/NLR, and 5
(10%) NLR.
4. Discussion
The results of the present study showed that the majority of
respondents routinely measured the systemic inflammatory
response and used the GPS/mGPS, mainly for research and
prognostication purposes and that the majority of respon-
dents reported that a measure of the systemic inflammatory
response should be adopted into clinical guidelines.
A small number of people responded to our survey (25%)
although this rate falls within the average response rate of
between 20 and 30% [10]. Factors that are known to improve
the survey response rate include incentives, reduced survey
length, reduced complexity of questions, and reminder emails
[10]. In the present study the questions were intentionally
simple and limited to 10 in total and a reminder email was sent
to encourage respondents but did not employ any incentive
for completing the survey.
The survey was sent to potential participants world-
wide with the majority to Asia and Europe. The majority
of respondents of this survey were surgeons (43%) with
oncologists making up a quarter of respondents.The location
of the respondents did not closely match the locations of
the potential survey participants.Those invited to participate
were mainly from Asia and Europe; however, only 29% of
respondents were from Asia while 55% were from Europe.
Perhaps this lack of response from Asia is due to cultural
differences which were not present in those from Europe
or due to greater language barriers. Whatever the reason,
the poor response rate from Asia was disappointing given
that the majority of work using these prognostic scores has
been carried out in Europe and Asia. In the present study,
respondents were asked to estimate how many patients with
cancer they had assessed using these systemic inflammation
based scores in each year. The response was approximately
100 per year. With this volume of work it could be considered
that those who respondedwere specialists and had an interest
in systemic inflammation based scores.
It has been widely reported that markers of the sys-
temic inflammatory response are good prognostic markers
in patients with cancer. The majority of survey respon-
dents reported that they routinely assessed the systemic
inflammatory response in patients with cancer and the
majority used this assessment for research or prognostication
purposes. This is not unexpected since the majority of
studies examining these scoring systems were performed for
research purposes or were performed retrospectively to aid
prognostication of patients into high and low risk groups.
Whilst CRP has been shown to have prognostic value in a
number of tumours, the mGPS, which utilises a combination
of CRP and albumin at standard thresholds, has been shown
to have superior prognostic value and obviates the problem of
different CRP threshold values being used within and across
different tumour types. In the present study, the majority of
respondents reported that theywould useGPS/mGPS as their
method of assessing the systemic inflammatory response.
This would appear to be consistent with the literature and
whilst the participants of this survey have an interest in this
field, it was not clear, prior to this survey, what views they had
on the clinical application of systemic inflammation based
prognostic scores, in particular which, if any, score that they
would prefer to use clinically.
Interestingly, only a small number of respondents
reported that they used assessment of the systemic inflam-
matory response to determine treatment allocation and this
is an area where proponents of these scoring systems would
hope to expand their use in order to better stratify patients to
appropriate treatment modalities [11]. Of the survey respon-
dents, 56% reported that they would use ameasure of the sys-
temic inflammatory response to stratify patients entering into
clinical trials and 57% said they would choosemGPS/GPS for
this. Moreover, of the survey respondents, 25% reported that
these scores were used in making decisions about palliative
chemotherapy, 21% in making decisions about allocation
of adjuvant therapy, and 12% in making decisions either
about adjuvant therapy or palliative chemotherapy. Only
4% reported that a measure of the systemic inflammatory
response would be of benefit in making decisions about
allocation of surgical treatment. This is of interest as the
majority of respondents were surgeons, with the majority of
research in these scoring systems having been undertaken by
surgeons, yet the consensus was that it would not be of benefit
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Figure 4: (a) Would you use a measure of the systemic inflammatory response to stratify patients entering into clinical trials? Respondents
(𝑛 = 55) and (b) which measure of the systemic inflammatory response would you use to stratify patients entering into clinical trials?
Respondents (𝑛 = 35).
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Figure 5: In which clinical scenario do you think a measure of the systemic inflammatory response offers most benefit to patients?
Respondents (𝑛 = 49).
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Figure 6: (a)Do you think that ameasure of the systemic inflammatory response should be adopted into clinical guidelines? Respondents (𝑛 =
57) and (b) which measure of the systemic inflammatory response respondants think should be included in clinical guidelines? Respondents
(𝑛 = 50).
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to allocate surgical treatment based on these scoring systems.
The basis of this approach is not clear. However it may be
that surgeons wish to operate on all patients with potentially
curable disease. It remains to be seen whether this approach
will bemaintained in the long term, particularly in aggressive
cancers such as pancreatic cancer where neoadjuvant therapy
is increasingly used as first line therapy.
Furthermore, recent work has suggested that markers
of the systemic inflammatory response may be useful as
a therapeutic target. The recent addition of an antiangio-
genic monoclonal antibody to VEGF therapy, such as Beva-
cizumab to standard chemotherapy regimens, has resulted
in improved efficacy of these regimens. However, recent
studies have reported that patients with a raised neutrophil
count, high NLR or mGPS 1 or 2, received no significant
survival benefit from these regimens [12–14]. In addition,
Botta and colleagues reported in their study that preoperative
systemic inflammatory status was a marker of resistance to
bevacizumab therapy [13]. Also, recent work has suggested
that the mGPS may be useful in stratifying oncological
treatment. Hurwitz et al. recently reported that Ruxolitinib (a
Janus Kinase 1 (JAK1)/Janus Kinase 2 (JAK2) inhibitor) along
with capecitabine improved overall survival and progression
free survival in patients with metastatic pancreatic cancer
with inflammation characterised by mGPS 1 or 2 [15].
Of the survey respondents, 80% reported that they felt
that a measure of the systemic inflammatory response should
be adopted into clinical guidelines and 60% reported that
GPS/mGPS would be their preference. For example, cancer
cachexia affects greater than 50% of patients with advanced
disease and its clinical definition and symptoms have been
intensively discussed in recent years [16, 17]. Recently, the
European School of Oncology Task Force conducted a review
of the literature on cancer cachexia. They concluded that
cachexia is a complex process but that, along with anorexia,
the presence of a systemic inflammatory response results
in the features of the disease [16]. Furthermore, Douglas
and McMillan (2014) recently proposed that the mGPS be
used as the basis for formation of an objective and clinically
relevant definition of cachexia [17]. The findings of the
present study would appear to confirm that the mGPS is the
most commonly used systemic inflammation based score and
therefore appropriate for forming the basis of an objective
definition of cancer cachexia.
The present study has a number of possible limitations.
Firstly, respondents did not have to enter their location in
order to complete the questionnaire,meaning the location for
all the respondents was not obtained. In all surveys there is a
tension between making the sample size as large as possible
in order to eliminate bias and asking questions appropriate to
those surveyed. In the present survey, we targeted those with
a known interest in systemic inflammation based prognostic
scores (those who had already published in this field) in
order tomaximise the number of appropriate andmeaningful
responses. The mGPS and NLR are the most popular scores
as they have the largest evidence base. Although other
systemic inflammation based prognostic scores such as the
derived NLR (dNLR), lymphocyte monocyte ratio (LMR),
and platelet-lymphocyte ratio (PLR) have been reported, they
have not established a sufficient body of evidence in the lit-
erature. Moreover, where they have been directly compared,
the mGPS had the greatest prognostic value in patients with
cancer, independent of age, sex, deprivation, and tumour
stage [4, 18]. Therefore, it is likely that the results of this
survey reflect the reality of attitudes towards the application
of these scores in those individuals with an interest in the
field. It was of interest that 43% of the respondents were
surgeons. This may reflect the activity of surgeons in this
field. Indeed, it is recognised that surgeons are key members
of the multidisciplinary team (MDT) that decides treatment
allocation. Irrespectively, this would confirm that the survey
was directed at clinicians in routine clinical practice.
In summary, the present study has shown that, in those
who responded, themajority routinelymeasured the systemic
inflammatory response in patients with cancer, with the
majority using the GPS/mGPS, mainly for research and
prognostication purposes. The majority reported that these
scoring systems were of most clinical benefit in making
decisions on adjuvant therapy and palliative chemotherapy
and that the systemic inflammatory response, as evidenced
by theGPS/mGPS, should be adopted into clinical guidelines,
such as a new, objective and clinically relevant definition of
cancer cachexia.
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